A persistent problem remains a challenge in HFpEF – patient heterogeneity.
We need the right patients for the right treatment, but how do we get it to them? We believe one approach to solving this issue is to improve patient segregation and endotyping.
Professor Morten Karsdal, CEO of Nordic Bioscience, elaborates on the topic and explains why measuring the right epitope of the right protein is advantageous compared to standard total protein arrays.
In this animated video of the Extracellular Matrix (ECM), we showcase how the Nordic Bioscience Protein Fingerprint neo-epitope technology provides serological quantification for ECM remodeling.
We are developing Tau-C, an assay that allows for the early detection of neuron loss before the onset of symptoms
Kim Henriksen, Director of Endocrinology and CNS at Nordic Bioscience, is introducing some of the work that we have done within the field of Alzheimer’s Disease.
In this Joint Tissue 3D animation, we showcase the potential benefit of Protein Fingerprint biomarkers for preclinical and clinical research in degenerative joint diseases.
There is an unmet medical need for predictive biomarkers that can guide patient selection and treatment decisions.
Christina presents how tumor fibrosis and collagen fragments can be used as biomarkers that can guide immune checkpoint inhibitor therapy.
We love collagens... and you should too!
The extracellular matrix (ECM) is the common denominator in all chronic diseases. When we decipher the tissue, we are essentially looking into a biological crystal ball that we can use to predict the course of disease progression.
Watch Dr. Morten Asser Karsdal, CEO of Nordic Bioscience, talk about the importance of collagens and the ECM at TEDx, Technical University of Denmark.
The video on this resource page explains how Nordic Bioscience's biomarkers can benefit drug development.
A simple blood sample can be quantified by the Protein Fingerprint Technology and be used as a sophisticated biomarker tool for tailoring treatment solutions, predicting and monitoring disease progression and treatment response.
We need better translational tools to evaluate drugs in preclinical models and prevent drug failure in the clinic. We believe biomarkers are the necessary translational tool.
Sarah presents how translational biomarkers can be used in pulmonary fibrosis.
HFpEF is predicted to become the predominant form of HF worldwide. It is a very heterogeneous clinical syndrome with a very high degree of morbidity. The syndrome is determined by age, comorbidities and fibrosis, and there is an unmet medical need for better diagnostic and prognostic biomarkers.
Alexander presents how Endotrophin can be used as a novel biomarker in HFpEF, using the PRO-C6 biomarker assay.
There are currently no approved disease-modifying osteoarthritis drugs (DMOADs) and only symptom relief treatments are available.
Watch Yi He present how our biomarkers have the potential to aid Osteoarthritis drug development in various stages.
Fecal calprotectin is already an established biomarker for inflammatory bowel disease. But because conventional calprotectin is measured in fecal samples there is low patient compliance and high day-to-day variance resulting in low precision and accuracy.
Watch Joachim present our exciting biomarker data from Nordic Bioscience’s novel serum calprotectin assay for inflammatory bowel disease.
Please don't hesitate to contact us if you have any questions or other inquiries.